Up to 105 Japanese men will be enrolled at 11 sites, with data aimed at supporting a future marketing authorisation submission.
To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the ...
News-Medical.Net on MSN
Study tests combined targeted radiopharmaceuticals and precision radiation for recurrent prostate cancer
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...
The UCLA trial is currently enrolling patients.
Various imaging modalities show low sensitivity for detecting pelvic lymph node invasion prior to surgery in patients with intermediate risk prostate cancer.
—These findings suggest that conventional imaging significantly underestimates the extent of disease in high-risk, biochemically recurrent prostate cancer, potentially impacting treatment decisions ...
New research suggests that men who take multivitamins after being diagnosed with prostate cancer may have a lower risk of cancer recurrence. In the overall study group, current multivitamin users ...
While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...
Patients who reported current multivitamin use had a lower risk of recurrence than patients who had never taken multivitamins. Patients with prostate cancer may have a lower risk of recurrence if they ...
Hosted on MSN
A True Game-Changer in Prostate Cancer: A Simple Genomic Test Can Tell Us Who Needs Hormone Therapy And Who Doesn’t
If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results